Galapagos extends discovery pact with Amgen

The service division of Belgium's Galapagos has extended its drug discovery pact with Amgen through 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen's discovery programs. Under the terms of the extended agreement, Galapagos gets an upfront fee of $2.4 million as a payment for 2007 research costs.

- see the press release on the deal
- here's the report on the deal from MarketWatch

Related Article:
Galapagos to buy UK's Inpharmatica. Report